Ascletis Targets Obesity Market with New Once-Monthly FDA Filings
Ascletis Pharma has filed two Investigational New Drug applications with the U.S. FDA, aiming to disrupt the obesity treatment landscape with long-acting, injectable therapies. The submissions focus on ASC36, a peptide amylin receptor agonist, and a co-formulation combining ASC36 with the GLP-1R/GIPR agonist ASC35.